近日，长春长生问题疫苗事件持续发酵，引爆舆论。7月22日，李克强总理就疫苗事件作出批示：此次疫苗事件突破人的道德底线，必须给全国人民一个明明白白的交代。
事已至此，唯有公开透明的处理方式，才能有效化解“问题疫苗”引发的公共卫生危机。
李克强总理就疫苗事件作出批示
Premier Li Keqiang said in an instruction that the vaccine case has crossed a moral line, and the nation deserves a clear explanation, the State Council said on its website on Sunday.
国务院官网22日发布消息称，李克强总理就疫苗事件作出批示：此次疫苗事件突破人的道德底线，必须给全国人民一个明明白白的交代。
▲资料图（来源：中国政府网）
The State Council should immediately send a group to investigate to uncover the truth as soon as possible, and any wrongdoing will be severely punished regardless of who is involved, Li said.
李克强在批示中要求，国务院要立刻派出调查组，对所有疫苗生产、销售等全流程全链条进行彻查，尽快查清事实真相，不论涉及到哪些企业、哪些人都坚决严惩不贷、绝不姑息。
国家药监局：立案调查
The State Drug Administration has launched an investigation of Changchun Chang-sheng Bio-tech Co, which was found to have fabricated production records for freeze-dried rabies vaccines for human use.
国家药品监督管理局对长春长生生物科技有限责任公司开展调查，发现该企业冻干人用狂犬病疫苗生产存在记录造假。
▲接受调查的长春长生生物科技有限公司生产的狂犬疫苗（图片来源：CGTN）
The cases of those suspected of violating laws will be transferred to public security departments, the authority said on Sunday.
7月22日，药监局表示，涉嫌犯罪的将移送公安机关。
Xu Jinghe, deputy head of the drug administration, said the company was found to have fabricated production and inspection records.
国家药品监督管理局副局长徐景和表示，现已查明，企业编造生产记录和产品检验记录。
Such activities are in violation of the country’s drug management law and related regulations on drug production, Xu said.
这些行为严重违法了《中华人民共和国药品管理法》，徐景和说。
In a notification on July 15, the drug administration ordered the company to stop producing the human rabies vaccine. It said no products involved in the inspection were currently being sold and all the vaccine involved had been removed.
国家药品监督局在15日的通告中责令该企业停止狂犬疫苗的生产。本次检查所有涉事批次产品尚未出厂和上市销售，全部产品已得到有效控制。
▲药监局对长春长生公司生产狂犬疫苗的调查通告（图片来源：CGTN）
The administration has also revoked the company’s certificate that is needed for production and sales of the vaccine.
药监局还回收了该企业用于生产和销售疫苗的证书。
除了狂犬疫苗，该公司生产的百白破疫苗也被曝出问题↓
Its remarks came amid public concerns about vaccine safety in China over the weekend, after it was also revealed that Changsheng Bio-tech was linked to a substandard adsorbed diphtheria-pertussis-tetanus, or ADPT, vaccine for infants.
上周末，随着长春长生公司再度被曝所生产的婴幼儿吸附无细胞百白破联合疫苗不符合规定，中国公众对疫苗安全表示担忧。
On Friday, the Jilin Provincial Drug Administration announced a penalty regarding Changchun Changsheng Bio-tech Co's substandard ADPT vaccine.
7月20日，吉林省食品药品监督局公布了对长春长生生物科技有限责任公司因生产吸附无细胞百白破联合疫苗不合规而进行的处罚。
The company was fined 2.58 million yuan ($282,000), and 859,000 yuan in assets from sales of the vaccine were confiscated.
该企业被处以罚金258万元，没收违法所得85.9万元。
The case was under investigation last year.
这起案件于去年接受调查。
Changsheng Bio-tech Co, parent company of Changchun Changsheng Bio-tech Co, revealed in November that 252,600 doses of the substandard ADPT vaccine that couldn't meet the standard of immunity results were all sold to Shandong province and had been recalled.
去年11月，长春长生科技有限责任公司的母公司——长生生物科技股份有限公司被曝销往山东省的不合格百白破疫苗共计 252600 支，这些疫苗不符合免疫效果的标准，已要求召回。
“The substandard ADPT vaccine won’t post safety threats to people’s health, but will reduce the expected immune effects,” Dingxiang-yuan, a professional medical website, said in an online reply to public concerns about the vaccine’s safety.
“该批次百白破疫苗效价指标不合格，可能影响免疫保护效果，但对人体安全性没有影响。”丁香园专业医药网对于公众对疫苗安全的担忧回复道。
The state drug administration confirmed on Sunday that it was discovered in October that one batch of Changsheng’s ADPT vaccine was substandard, and its production of ADPT has been suspended since then.
7月22日，药监局证实去年10月发现长生公司生产的某批次吸附无细胞百白破联合疫苗不符合规定，此后这种疫苗停产。
A plan for reinoculation of those affected was worked out in February.
有关补种工作已于今年2月进行了部署。
长生生物回应：十分自责和愧疚
The Shenzhen Stock Exchange announced that it sent letters to Changsheng Bio-tech Co on Sunday, calling for early disclosure of the two cases to the public.
深圳证券交易所22日称，已向长生生物科技股份有限公司发出关注函，要求其尽早向公众披露两起案件的信息。
“We will maintain strict supervision over the listed company’s information disclosure responsibility according to the law and guarantee legal rights of investors,” it said in the online announcement.
深交所在线上公告中指出，将依法全面从严监管上市公司信息披露行为，切实保护投资者合法权益。
The Shenzhen Stock Exchange posted a reply from Changsheng Bio-tech Co later in the afternoon on its website. It says, “We feel very remorseful and guilty about what has happened, and we apologize to all those vaccinated and investors.”
深交所于当日晚间发布了长生生物科技公司的回复，其中提到：“我们感到十分的自责和愧疚，再次向各位接种者和投资者表示深深的歉意。”
The company added that it will learn a lesson.
该企业还表示将引以为戒。
长生生物官网被黑：不搞你，对不起祖国的花朵
7月23日，长生生物官网首页被黑客攻击，并配图“不搞你，对不起祖国的花朵”。
多方呼吁严惩，期待公开透明的处理方式
Several state media called for severe punishment and stricter supervision of vaccines. People’s Daily released a commentary on Sunday saying that drugmakers should stick to moral principles and make life their priority rather than profits.
多家官媒呼吁严惩疫苗问题，加强疫苗监管。《人民日报》22日发表评论文章称，制药企业必须守住起码的道德底线，必须以“敬畏生命”为信条。
The authorities need to release whatever information they know about the incident to the public as soon as possible.
事已至此，唯有公开透明的处理方式，才能有效化解“问题疫苗”引发的公共卫生危机。
It is not just to pacify the public in the wake of this particular incident. It is also for a thorough overhaul of the industry as vaccines are directly related to people’s health, particularly children.
这不仅是为了平息舆论，更是为了整顿整个疫苗行业。毕竟这一行业关系着全国人民的生命健康，尤其牵涉着少年儿童，牵涉着祖国的未来。
